Apexigen- Warrants (29/07/2027) EBIT

As of the most recent data (June 2023), APGNW shows a EBIT of $-28M. That compares with $-1.8B in the prior-year period — up 98.5% year over year. That is below the sector sector average of $-6.4M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, APGNW's EBIT is now $-28M (was $-1.8B) — a 98.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Apexigen- Warrants (29/07/2027) is outperforming or lagging.

The its sector sector average EBIT is about $-6.4M. Apexigen- Warrants (29/07/2027) is at $-28M, which is lower that average. That is roughly 334.6% below the sector mean. Use the comparison chart on this page to see how APGNW stacks up against individual peers as well.

Tracking APGNW's ebit over time shows whether Apexigen- Warrants (29/07/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $-28M That compares with $-1.8B in the prior-year period — up 98.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Apexigen- Warrants (29/07/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-28M) with ownership activity and broader fundamentals.